Instead of expanding at its New Jersey headquarters, Legend Biotech opened its new R&D center in Philadelphia. This strategic move aims to attract specialized scientific talent by deliberately locating in a key innovation hub for cell therapy, demonstrating a "go to the talent" growth strategy.

Excel Data exemplifies a modern global startup structure. With three of four co-founders based in India, they built their core tech team there to leverage the big data talent pool. Meanwhile, the CEO relocated to the Bay Area to establish the go-to-market and sales functions, capitalizing on both regions' strengths.

Recent billion-dollar successes in the French biotech ecosystem, such as Abivax and Medincel, are largely credited to their management teams. These leaders often have significant experience working in the US and other countries. This global perspective enables them to develop assets for a worldwide market, navigate different regulatory environments, and attract international funding, breaking the mold of previously localized French biotechs.

The company leverages its remote structure by hiring strategically. A Spanish team is located near suppliers for better sourcing and relationships, while a British team focuses on the consumer market. This intentional geographic distribution optimizes both supply chain and marketing efforts.

Instead of traditional regional HQs, firms should adopt a "capability-first" model. This involves strategically placing functions where excellence exists: basic science in Japan, clinical scale in China, and biologics in Korea. This creates a more efficient, interconnected global R&D engine, breaking from geography-based silos.

The shift to remote work unlocked a global talent pool. For specialized roles, the advantage of hiring the best possible person, regardless of location, is far greater than the benefits of in-person collaboration. The leadership challenge shifts from managing location to enabling distributed top-tier talent.

Founded in Minnesota, Cellcuity taps the University of Minnesota and the region's medical device industry for scientific talent. For specialized roles like clinical development, it embraces a distributed team, demonstrating a viable model for building a biopharma company outside of traditional hubs.

Beyond a supportive ecosystem, CDR Life's CEO highlights Switzerland's dense concentration of well-trained life science professionals from big pharma, biotech, and top universities as its most critical advantage. This makes it easier to hire and retain the specialized talent essential for a biotech's success.

The future biotech landscape is not US vs. China, but a "multipolar" world where savvy companies operate as "hybrid biotechs." They will selectively build bridges, cherry-picking talent, capabilities, and operational models across the US, Europe, and China to accelerate development.